BioPharmaTrend
Latest News
All Topics
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Newsletter
Login/Join
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
back to Directory

LabGenius

LabGenius logo

Website
https://www.labgeni.us
Founded
2012
Patents
2
Publications
7

Technologies

AI Companies (Drug Discovery)

LabGenius is the first biopharmaceutical company developing next generation protein therapeutics using a machine learning-driven evolution engine (EVA™️).

Our protein engineering platform integrates several bleeding edge technologies from the fields of machine learning, synthetic biology, and robotics. We use advanced deep-learning neural networks to explore protein fitness landscapes and improve multiple drug properties simultaneously.

synthetic biology protein engineering protein therapeutics


Posts Mentioning This Company

LabGenius' AI-Driven Antibody Discovery Platform Reimagining T-cell Engager Optimisation

LabGenius Showcases AI-Driven Antibody Discovery Platform in a T-cell Engager Demonstration

May 15, 2023  
London-based LabGenius, known for its innovative approach to antibody discovery, recently revealed impressive results from its research platform demonstration project. This project showcased the company's machine learning-driven lead optimization capacity, which successfully delivered T-cell engagers (TCEs) with unprecedented tumor-killing selectivity. The results were presented at the 2023 Protein Engineering and …
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development

 

R&D Platform

EVA - an autonomous AI-driven evolution engine for the discovery of high-value protein components.

News

  • 2024-05-21
    LabGenius Secures £35 Million to Enhance ML-Driven Antibody Discovery

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Newsletter
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.